• Publications
  • Influence
Boron neutron capture therapy in the treatment of locally recurred head-and-neck cancer: final analysis of a phase I/II trial.
Most patients who have inoperable, locally advanced head-and-neck carcinoma that has recurred at a previously irradiated site respond to boronophenylalanine-mediated BNCT, but cancer recurrence after BnCT remains frequent. Expand
L-boronophenylalanine-mediated boron neutron capture therapy for malignant glioma progressing after external beam radiation therapy: a Phase I study.
BNCT administered with an l-BPA-F dose of up to 400 mg/kg as a 2-hour infusion is feasible in the treatment of malignant gliomas that recur after conventional radiation therapy. Expand
Boron neutron capture therapy of brain tumors: clinical trials at the Finnish facility using boronophenylalanine
BPA-based BNCT has been relatively well tolerated both in previously irradiated and unirradiated glioblastoma patients, and Efficacy comparisons with conventional photo radiation are difficult due to patient selection and confounding factors such as other treatments given, but the results support continuation of clinical research on BPA-by-BNCT. Expand
Boron neutron capture therapy in the treatment of locally recurred head and neck cancer.
Boron neutron capture therapy is effective and safe in the treatment of inoperable, locally advanced head and neck carcinomas that recur at previously irradiated sites. Expand
Boron neutron capture therapy (BNCT) in Finland: technological and physical prospects after 20 years of experiences.
In this technical review, the research work in the field of medical physics is discussed to form the groundwork for the Finnish BNCT patient treatments, as well as the possibilities to further develop and optimize the method in the future. Expand
Metamorphosis of a 35 Year-Old TRIGA Reactor into a Modern BNCT Facility
Using FiR 1, a 250kW TRIGA reactor as a neutron source for BNCT was screened as a viable option in 1990, as the future of the reactor was questioned. By the initiative of the medical radio isotopeExpand
Boron Neutron Capture Therapy of Brain Tumors: Clinical Trials at the Finnish Facility Using Boronophenylalanine
Two clinical trials are currently running at the Finnish dedicated boron neutron capture therapy (BNCT) facility. Between May 1999 and December 2001, 18 patients with supratentorial glioblastoma wereExpand
The alanine detector in BNCT dosimetry: dose response in thermal and epithermal neutron fields.
Alanine detector application in neutron fields for medical purpose is limited by its sensitivity but that it is a useful tool as supplement to other detectors and verification of neutron source descriptions. Expand
MAGIC polymer gel for dosimetric verification in boron neutron capture therapy
The results support the feasibility of using MAGIC gel in BNCT dosimetry and the measured and normalized dose distribution in the epithermal neutron beam was compared with the dose distribution calculated by computer simulation. Expand
MCNP study for epithermal neutron irradiation of an isolated liver at the Finnish BNCT facility.
The results show, that the epithermal field penetrates deeper into the liver and creates a build-up distribution of the boron dose, which strongly encourage further studying of irradiation arrangement of an isolated liver withEpithermal neutron fields. Expand